GW Pharmaceuticals (NYSE:GWPH)
- CEO:Justin Gover
GW Pharmaceuticals (NYSE:GWPH) Stock Price
GW Pharmaceuticals (NYSE:GWPH) Company Overview
Pioneers from the start, GW Pharmaceuticals (NASDAQ: GWPH) was founded in 1998 by Doctors Geoffrey Guy and Brian Whittle. That year, they obtained the necessary licenses to cultivate, possess and supply cannabis in order to carry out scientific research around the plant.
From there, the company went on to create Sativex in 2014, a cannabinoid drug designed as treatment for multiple sclerosis (MS) which was the first cannabis derivative to receive market approval in any country.
And in 2018, the company came out with Epidiolex, which remains the only cannabis drug currently approved by the US Food and Drug Administration. Epidiolex is used to treat epilepsy.
To date Over 12,000 patients have received Epidiolex prescriptions since launch, with 2019 Q2 net sales of $68.4M made from the product. That same quarter, the company reported a revenue of $72 million.
- Address:Sovereign House, Vision Park Chivers Way Histon, Cambridge CB24 9BZ, UK
GW Pharmaceuticals (NYSE:GWPH) Financials
The latest update from the companyClick Here
Stay updated about
Signup to get updates.
Dr. Geoffrey Guy
Chairman & Founder
Guy has been actively involved in scientific innovation, medical research and global drug development for his entire career. Prior to his role at GW, Dr Guy served as Chairman and Chief Executive of Ethical Holdings plc, a NASDAQ-quoted drug delivery Company.
He has 21 years’ experience in the pharmaceutical industry, and raised initial rounds of private capital for the company, following which he led its initial public offering on the AIM stock exchange in London in 2001, and more recently led GW’s initial public offering on Nasdaq in 2013.
Most recently, Mr. Tovey acted as the Vice President of Global Marketing Operations, where he was responsible for worldwide marketing activities on a portfolio of UCB products generating over €2.0 billion in annual sales.